Work

The Alzheimer’s Prevention Initiative Generation Program: Evaluating Cnp520 Efficacy in the Prevention of Alzheimer’s Disease

Year: 2017

Type: article

Source: The Journal of Prevention of Alzheimer s Disease

DOI: 10.14283/jpad.2017.37

Authors: C. Lopez Lopez, A. Caputo, F. Liu, M.E. Riviere, M.-L. Rouzade-Dominguez, R.G. Thomas, J.B. Langbaum, R. Lenz, E.M. Reiman, A. Graf, P.N. Tariot

Institutions: Novartis (Switzerland), University of California San Diego, Banner Alzheimer’s Institute, Amgen (United States)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Alzheimer's Association, Abbott Laboratories, Amgen, Eli Lilly and Company, Pfizer, Biogen, Arizona Department of Health Services, GHR Foundation, NOMIS Stiftung, Foundation for Biomedical Research and Innovation, National Institutes of Health, Genentech, Novartis Pharma, National Institute on Aging

Awards: G1606131442, G2298519484, G3540482749, Alzheimer's Prevention Initiative ADAD Colombia Trial, Alzheimer's Disease Cooperative Study (ADCS), G5159660262, Brain Imaging, APOE & the Preclinical Course of Alzheimer's Disease, Alzheimer's Prevention Initiative APOE4 Trial, Arizona Alzheimer's Disease Core Center, G9000106143, G9000159448

OpenAlex ID: W2767538090

FWCI: 4.862

Cites: 11

Cited by: 36

Related to: 10